Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

283.22 +3.19 (+1.14%)
Streaming Delayed Price Updated: 12:30 PM EST, Jan 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 185,625
Open 277.40
Bid (Size) 282.73 (1)
Ask (Size) 283.45 (1)
Prev. Close 280.03
Today's Range 277.40 - 284.62
52wk Range 160.19 - 286.39
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill

Performance

YTD
+10.27%
+10.27%
1 Month
+8.48%
+8.48%
3 Month
+22.33%
+22.33%
6 Month
+43.58%
+43.58%
1 Year
+48.38%
+48.38%

More News

Read More
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
From Insulet Corporation
Via Business Wire
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Via Investor's Business Daily
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Insulet Corporation
Via Business Wire
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Looking Into Insulet's Recent Short Interest
Via Benzinga
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Via Investor's Business Daily
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Via Chartmill
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
Inari Medical Stock Gets RS Rating Upgrade
Via Investor's Business Daily
Decoding 11 Analyst Evaluations For Insulet
Via Benzinga
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
Novocure Stock Earns 96 RS Rating
Via Investor's Business Daily
Peering Into Insulet's Recent Short Interest
Via Benzinga
NASDAQ:PODD qualifies as a high growth stock and is consolidating.
Via Chartmill
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Top 4 Health Care Stocks That May Plunge This Quarter
Via Benzinga
9 Analysts Have This To Say About Insulet
Via Benzinga
S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?
Via Benzinga
Topics Stocks
Exposures US Equities
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues
Via Investor's Business Daily
High growth, ROE and relative strength for NASDAQ:PODD, growth investors may appreciate this.
Via Chartmill
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.